© 2008, Columbia Laboratories, Inc. All rights reserved.

 

Please note that the product information provided on this website is intended only for residents of the United States.

In IVF-ET cycles—

 

Efficacy Comparable to IM Progesterone Across Age Groups1

 
Study design: Results of a prospective study with historical controls of 206 women receiving progesterone for an IVF-ET cycle; less than one third of patients also underwent ICSI. Patients eligible for the study received Crinone 8% (90 mg QD) starting on the evening of oocyte retrieval. Patients in the historical control group received IM progesterone (50 mg QD) starting on the evening of oocyte retrieval.
  • This study demonstrates comparable efficacy despite age (in the <35 y and 35–39 y age groups)
  • There are too few subjects >39 y to evaluate that age group

Proven pregnancy outcomes despite lower midluteal serum progesterone levels

  • Crinone 8%: 57.7 ± 7.4 ng/mL versus IM progesterone: 94.3 ± 8.8 ng/mL (P=.0015)

Reference: 1. Chantilis SJ, Zeitoun KM, Patel SI, et al. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829.